Loncar Cancer Financials
| CNCR Etf | USD 14.38 0.03 0.21% |
Net Expense Ratio 0.0079 |
Loncar |
The data published in Loncar Cancer's official financial statements typically reflect Loncar Cancer's business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Loncar Cancer's quantitative information. For example, before you start analyzing numbers published by Loncar accountants, it's essential to understand Loncar Cancer's liquidity, profitability, and earnings quality within the context of the Loncar Investments space in which it operates.
Loncar Cancer Etf Summary
Loncar Cancer competes with Vanguard Consumer, Vanguard Financials, Vanguard Information, Vanguard Consumer, and Vanguard Utilities. The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the funds index provider, as having a high strategic focus on the development of drugs that harness the bodys own immune system to fight cancer. Loncar Cancer is traded on NASDAQ Exchange in the United States.| Instrument | USA Etf View All |
| Exchange | NASDAQ Exchange |
| ISIN | US26922A8264 |
| CUSIP | 26922A826 |
| Region | North America |
| Investment Issuer | Exchange Traded Concepts |
| Etf Family | Loncar Investments |
| Fund Category | Sector |
| Portfolio Concentration | Health Care |
| Benchmark | Dow Jones Industrial |
| Phone | NA |
| Currency | USD - US Dollar |
Loncar Cancer Key Financial Ratios
Loncar Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Loncar Cancer's current stock value. Our valuation model uses many indicators to compare Loncar Cancer value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Loncar Cancer competition to find correlations between indicators driving Loncar Cancer's intrinsic value. More Info.Loncar Cancer Immunotherapy is the top ETF in price to earning as compared to similar ETFs. It also is the top ETF in price to book as compared to similar ETFs fabricating about 0.08 of Price To Book per Price To Earning. The ratio of Price To Earning to Price To Book for Loncar Cancer Immunotherapy is roughly 12.38 . Comparative valuation analysis is a catch-all technique that is used if you cannot value Loncar Cancer by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Loncar Cancer Immuno Systematic Risk
Loncar Cancer's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Loncar Cancer volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-eight with a total number of output elements of thirty-three. The Beta measures systematic risk based on how returns on Loncar Cancer Immuno correlated with the market. If Beta is less than 0 Loncar Cancer generally moves in the opposite direction as compared to the market. If Loncar Cancer Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Loncar Cancer Immuno is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Loncar Cancer is generally in the same direction as the market. If Beta > 1 Loncar Cancer moves generally in the same direction as, but more than the movement of the benchmark.
Steps to analyze company Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Loncar Cancer is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Loncar has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Loncar Cancer's financials are consistent with your investment objective using the following steps:- Review Loncar Cancer's balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand Loncar Cancer's liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare Loncar Cancer's financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Loncar Cancer's stock is overvalued or undervalued.
Loncar Cancer Thematic Clasifications
Loncar Cancer Immunotherapy is part of several thematic ideas from Health Care ETFs to Robots And Drones. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic IdeasLoncar Cancer December 2, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Loncar Cancer help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Loncar Cancer Immunotherapy. We use our internally-developed statistical techniques to arrive at the intrinsic value of Loncar Cancer Immunotherapy based on widely used predictive technical indicators. In general, we focus on analyzing Loncar Etf price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Loncar Cancer's daily price indicators and compare them against related drivers.
| Information Ratio | (0.08) | |||
| Maximum Drawdown | 11.54 | |||
| Value At Risk | (3.72) | |||
| Potential Upside | 4.08 |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Loncar Cancer Immunotherapy. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
The market value of Loncar Cancer Immuno is measured differently than its book value, which is the value of Loncar that is recorded on the company's balance sheet. Investors also form their own opinion of Loncar Cancer's value that differs from its market value or its book value, called intrinsic value, which is Loncar Cancer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Loncar Cancer's market value can be influenced by many factors that don't directly affect Loncar Cancer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Loncar Cancer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Loncar Cancer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Loncar Cancer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.